Discovery of 4-amino-3-arylsulfoquinolines, a novel non-acetylenic chemotype of metabotropic glutamate 5 (mGlu 5 ) receptor negative allosteric modulators

This publication has 18 references indexed in Scilit:

• Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials
  Science Translational Medicine, 2016
• The role of metabotropic glutamate receptor 5 in the pathogenesis of mood disorders and addiction: combining preclinical evidence with human Positron Emission Tomography (PET) studies
  Frontiers in Neuroscience, 2015
• Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain
  Nature, 2014
• Mavoglurant as a treatment for Parkinson’s disease
  Expert Opinion on Investigational Drugs, 2014
• Randomised clinical trial: effects of monotherapy with ADX10059, a mGluR5 inhibitor, on symptoms and reflux events in patients with gastro-oesophageal reflux disease
  Alimentary Pharmacology & Therapeutics, 2011
• Metabotropic Glutamate Receptors: Physiology, Pharmacology, and Disease
  Annual Review of Pharmacology and Toxicology, 2010
• 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]- pyridine: A Potent and Highly Selective Metabotropic Glutamate Subtype 5 Receptor Antagonist with Anxiolytic Activity
  Journal of Medicinal Chemistry, 2002
• [3H]-M-MPEP, a Potent, Subtype-Selective Radioligand for the Metabotropic Glutamate Receptor Subtype 5
  Bioorganic & Medicinal Chemistry Letters, 2002
• Selective mGluR5 antagonists MPEP and SIB‐1893 decrease NMDA or glutamate‐mediated neuronal toxicity through actions that reflect NMDA receptor antagonism
  British Journal of Pharmacology, 2000
• Molecular Diversity of Glutamate Receptors and Implications for Brain Function
  Science, 1992